JP2010504361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010504361A5 JP2010504361A5 JP2009529432A JP2009529432A JP2010504361A5 JP 2010504361 A5 JP2010504361 A5 JP 2010504361A5 JP 2009529432 A JP2009529432 A JP 2009529432A JP 2009529432 A JP2009529432 A JP 2009529432A JP 2010504361 A5 JP2010504361 A5 JP 2010504361A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- formulation
- fragment
- 7f3com
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 7
- 238000002360 preparation method Methods 0.000 claims 5
- 108010002335 Interleukin-9 Proteins 0.000 claims 4
- 229910019142 PO4 Inorganic materials 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 4
- 239000010452 phosphate Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 238000001542 size-exclusion chromatography Methods 0.000 claims 3
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 claims 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims 2
- 230000006399 behavior Effects 0.000 claims 2
- 238000002983 circular dichroism Methods 0.000 claims 2
- 238000009295 crossflow filtration Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 238000001370 static light scattering Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100026244 Interleukin-9 receptor Human genes 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 108040006862 interleukin-9 receptor activity proteins Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000006432 protein unfolding Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84723906P | 2006-09-25 | 2006-09-25 | |
| US94999907P | 2007-07-16 | 2007-07-16 | |
| PCT/US2007/079403 WO2008039761A2 (en) | 2006-09-25 | 2007-09-25 | Stabilized antibody formulations and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010504361A JP2010504361A (ja) | 2010-02-12 |
| JP2010504361A5 true JP2010504361A5 (enExample) | 2010-11-18 |
Family
ID=39230903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009529432A Pending JP2010504361A (ja) | 2006-09-25 | 2007-09-25 | 安定した抗体製剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100129379A1 (enExample) |
| EP (1) | EP2066350A4 (enExample) |
| JP (1) | JP2010504361A (enExample) |
| KR (1) | KR20090060453A (enExample) |
| AU (1) | AU2007300221A1 (enExample) |
| CA (1) | CA2663892A1 (enExample) |
| WO (1) | WO2008039761A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008232903B9 (en) * | 2007-03-30 | 2013-09-05 | Medimmune Llc | Antibodies with decreased deamidation profiles |
| TWI661833B (zh) * | 2007-11-30 | 2019-06-11 | 百慕達商艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| WO2010042705A1 (en) * | 2008-10-09 | 2010-04-15 | Medimmune, Llc | Antibody formulation |
| US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
| US10005830B2 (en) | 2009-03-05 | 2018-06-26 | Ablynx N.V. | Antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| NZ613809A (en) * | 2009-05-04 | 2015-02-27 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| PT2473528E (pt) | 2009-09-03 | 2015-03-04 | Ablynx NV | Formulações estáveis de polipéptidos e seus usos |
| AU2011212440B2 (en) | 2010-02-04 | 2015-01-22 | Csl Behring Ag | Immunoglobulin preparation |
| EP2361636A1 (en) | 2010-02-26 | 2011-08-31 | CSL Behring AG | Immunoglobulin preparation and storage system for an immunoglobulin preparation |
| EP2613857B1 (en) * | 2010-07-30 | 2018-05-30 | MedImmune, LLC | Method for purifying immunoconjugates |
| MX344727B (es) | 2010-11-11 | 2017-01-05 | Abbvie Biotechnology Ltd | Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. |
| ES2630012T3 (es) | 2010-12-02 | 2017-08-17 | Oncolytics Biotech Inc. | Formulaciones virales liofilizadas |
| EA201390810A1 (ru) | 2010-12-02 | 2013-09-30 | Онколитикс Байотек Инк. | Жидкие вирусные составы |
| WO2012170742A2 (en) * | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
| US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
| UA115789C2 (uk) * | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| US20160017024A1 (en) * | 2013-03-12 | 2016-01-21 | Five Prime Therapeutics, Inc. | Fam150a, fam150b, and fam150 antagonists and uses thereof |
| CR20160132A (es) | 2013-08-12 | 2016-08-25 | Genentech Inc | Composiciones y método para tratar condiciones asociadas con el complemento |
| SG11201608868PA (en) * | 2014-05-01 | 2016-11-29 | Genentech Inc | Anti-factor d antibody variants and uses thereof |
| CA2968915A1 (en) | 2014-12-03 | 2016-06-09 | Csl Behring Ag | Pharmaceutical product with increased stability comprising immunoglobulins |
| HK1250040A1 (zh) | 2015-03-31 | 2018-11-23 | Sorriso Pharmaceuticals, Inc. | 多肽 |
| CA2981098A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Peptide construct having a protease-cleavable linker |
| EP3368074A2 (en) | 2015-10-30 | 2018-09-05 | Hoffmann-La Roche AG | Anti-factor d antibodies and conjugates |
| EP3368090A1 (en) * | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-factor d antibody variant conjugates and uses thereof |
| EP3435982A1 (en) | 2016-03-31 | 2019-02-06 | VHsquared Limited | Compositions |
| CN106990192B (zh) * | 2017-04-17 | 2019-05-21 | 大连工业大学 | 一种测定胶原蛋白分子质量的方法 |
| MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
| EP3986931A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| AU2020294980A1 (en) | 2019-06-21 | 2022-02-17 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| AU2020395148A1 (en) * | 2019-12-06 | 2022-06-23 | Theratechnologies Inc. | Sortilin binding conjugate compounds, compositions and uses thereof for treating cancer |
| BR112022012064A2 (pt) * | 2019-12-20 | 2022-08-30 | Anthos Therapeutics Inc | Formulação de distribuição de fármaco intravenosa, frasco compreendendo a mesma e método de tratamento de um sujeito acometido por ou em risco de desenvolver um distúrbio tromboembólico |
| AU2021265591A1 (en) * | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| US20230167153A1 (en) | 2020-05-01 | 2023-06-01 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| IL309349A (en) * | 2021-06-14 | 2024-02-01 | argenx BV | Antibodies against interleukin 9 and methods of using them |
| WO2025101487A1 (en) * | 2023-11-06 | 2025-05-15 | Bruker Cellular Analysis, Inc. | Affinity assay for microfluidic devices |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| ZA200506159B (en) * | 2003-02-10 | 2006-10-25 | Elan Pharm Inc | Immunoglobulin formulation and method of preparation thereof |
| AU2004229501B2 (en) * | 2003-04-11 | 2011-08-18 | Medimmune, Llc | Recombinant IL-9 antibodies and uses thereof |
| EP1713502A1 (de) * | 2004-02-12 | 2006-10-25 | MERCK PATENT GmbH | Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern |
| EP1755673B1 (en) * | 2004-04-12 | 2014-07-23 | MedImmune, LLC | Anti-il-9 antibody formulations and uses thereof |
-
2007
- 2007-09-25 KR KR1020097008540A patent/KR20090060453A/ko not_active Withdrawn
- 2007-09-25 AU AU2007300221A patent/AU2007300221A1/en not_active Abandoned
- 2007-09-25 JP JP2009529432A patent/JP2010504361A/ja active Pending
- 2007-09-25 EP EP07843136A patent/EP2066350A4/en not_active Withdrawn
- 2007-09-25 CA CA002663892A patent/CA2663892A1/en not_active Abandoned
- 2007-09-25 WO PCT/US2007/079403 patent/WO2008039761A2/en not_active Ceased
- 2007-09-25 US US12/442,655 patent/US20100129379A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010504361A5 (enExample) | ||
| Sun et al. | Cationic nanoparticles directly bind angiotensin-converting enzyme 2 and induce acute lung injury in mice | |
| ES2893861T3 (es) | Formulaciones de anticuerpo estables, acuosas | |
| TWI798199B (zh) | 癌症治療 | |
| JP2011057695A (ja) | 呼吸器の症状を治療又は予防する方法 | |
| US9175066B2 (en) | Compositions containing HC-HA complex and methods of use thereof | |
| RU2770366C2 (ru) | Препараты даптомицина | |
| JP2007514664A5 (enExample) | ||
| US20220211799A1 (en) | Compositions and methods for modulating complement activity | |
| US20220160820A1 (en) | Modulators of complement activity | |
| Ramezani et al. | A comparative study on the physicochemical and biological stability of IgG1 and monoclonal antibodies during spray drying process | |
| Freches et al. | PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab’antibody fragment after pulmonary delivery in three different species | |
| TW202402290A (zh) | 癌症治療 | |
| WO2021249548A1 (zh) | 一种新型冠状病毒抗体的药物组合物及其用途 | |
| WO2018121578A1 (zh) | 稳定的包含cd147单克隆抗体的药物制剂 | |
| Zheng et al. | Supramolecular nanofibers ameliorate Bleomycin‐induced pulmonary fibrosis by restoring autophagy | |
| Ouyang et al. | A citrullinated histone H3 monoclonal antibody for immune modulation in sepsis | |
| EP2138513B1 (en) | Pharmaceutical compositions of antibodies for diseases caused by viruses | |
| WO2021249373A1 (zh) | 一种稳定的高浓度抗人il-5单克隆抗体液体制剂 | |
| TWI676624B (zh) | 新穎化合物 | |
| TWI740034B (zh) | 治療癌症之肽 | |
| Lee et al. | Sequential nanoparticle therapy targeting neutrophil hyperactivation to prevent neutrophil-induced pulmonary fibrosis | |
| JP7687637B2 (ja) | 抗ウイルス活性を有するペプチド、当該ペプチドを含む抗ウイルス剤、当該抗ウイルス剤の製造方法 | |
| JP6247241B2 (ja) | 抗体処方 | |
| WO2018178594A1 (fr) | Prévention d'une infection par le virus respiratoire syncytial dans les voies respiratoires supérieures |